Saphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery
bypass graft surgery (CABG). Despite advances in surgical techniques and …

Hypercholesterolemia is a leading cause of cardiovascular morbidity and mortality.
Accordingly, efforts to lower apolipoprotein B–containing lipoproteins in plasma are the …

The 2021 guidelines primary panel selected clinically relevant questions and produced
updated recommendations, on the basis of important new findings that have emerged since …

Abstract Background and aims This European Atherosclerosis Society (EAS) Task Force
provides practical guidance for combination therapy for elevated low-density lipoprotein …

Background Many patients with acute coronary syndrome have concurrent metabolic risk
factors that affect risk of major adverse cardiovascular events (MACE). We aimed to assess …

Background: Despite advances in surgery and pharmacotherapy, there remains significant
residual ischemic risk after coronary artery bypass grafting surgery. Methods: In REDUCE-IT …

Aims Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and
normal-to-moderately impaired renal function. It is not known whether proprotein convertase …

In 2003, clinical observations led to the discovery of the involvement of proprotein
convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies …

Background Cholesterol reduction with proprotein convertase subtilisin-kexin type 9
inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients …

Coronary artery disease (CAD) is treated with medical therapy with or without percutaneous
coronary intervention (PCI) or coronary artery bypass grafting (CABG). The latter 2 options …